Literature DB >> 18158339

Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension.

Robert Fischer1, Ralf Dechend, Fatimunnisa Qadri, Marija Markovic, Sandra Feldt, Florian Herse, Joon-Keun Park, Andrej Gapelyuk, Ines Schwarz, Udo B Zacharzowsky, Ralph Plehm, Erdal Safak, Arnd Heuser, Alexander Schirdewan, Friedrich C Luft, Wolf-Hagen Schunck, Dominik N Muller.   

Abstract

We compared the effect n-3 polyunsaturated fatty acids (PUFAs) with direct renin inhibition on electrophysiological remodeling in angiotensin II-induced cardiac injury. We treated double-transgenic rats expressing the human renin and angiotensinogen genes (dTGRs) from week 4 to 7 with n-3 PUFA ethyl-esters (Omacor; 25-g/kg diet) or a direct renin inhibitor (aliskiren; 3 mg/kg per day). Sprague-Dawley rats were controls. We performed electrocardiographic, magnetocardiographic, and programmed electrical stimulation. Dietary n-3 PUFAs increased the cardiac content of eicosapentaenoic and docosahexaenoic acid. At week 7, mortality in dTGRs was 31%, whereas none of the n-3 PUFA- or aliskiren-treated dTGRs died. Systolic blood pressure was modestly reduced in n-3 PUFA-treated (180+/-3 mm Hg) compared with dTGRs (208+/-5 mm Hg). Aliskiren-treated dTGRs and Sprague-Dawley rats were normotensive (110+/-3 and 119+/-6 mm Hg, respectively). Both n-3 PUFA-treated and untreated dTGRs showed cardiac hypertrophy and increased atrial natriuretic peptide levels. Prolonged QRS and QT(c) intervals and increased T-wave dispersion in dTGRs were reduced by n-3 PUFAs or aliskiren. Both treatments reduced arrhythmia induction from 75% in dTGRs to 17% versus 0% in Sprague-Dawley rats. Macrophage infiltration and fibrosis were reduced by n-3 PUFAs and aliskiren. Connexin 43, a mediator of intermyocyte conduction, was redistributed to the lateral cell membranes in dTGRs. n-3 PUFAs and aliskiren restored normal localization to the intercalated disks. Thus, n-3 PUFAs and aliskiren improved electrical remodeling, arrhythmia induction, and connexin 43 expression, despite a 70-mm Hg difference in blood pressure and the development of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158339     DOI: 10.1161/HYPERTENSIONAHA.107.103143

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  26 in total

Review 1.  DHA derivatives of fish oil as dietary supplements: a nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity.

Authors:  Yonggang Ma; Merry L Lindsey; Ganesh V Halade
Journal:  Expert Opin Drug Discov       Date:  2012-06-24       Impact factor: 6.098

2.  Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts.

Authors:  Jinghai Chen; Gregory C Shearer; Quanhai Chen; Chastity L Healy; April J Beyer; Vijaya B Nareddy; A Martin Gerdes; William S Harris; Timothy D O'Connell; Dajun Wang
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

3.  Connecting the renin-angiotensin-aldosterone system with sudden death.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2011-07       Impact factor: 4.599

4.  Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction.

Authors:  Nicola Wilck; Lajos Markó; András Balogh; Kristin Kräker; Florian Herse; Hendrik Bartolomaeus; István A Szijártó; Maik Gollasch; Nadine Reichhart; Olaf Strauss; Arnd Heuser; Damian Brockschnieder; Axel Kretschmer; Ralf Lesche; Florian Sohler; Johannes-Peter Stasch; Peter Sandner; Friedrich C Luft; Dominik N Müller; Ralf Dechend; Nadine Haase
Journal:  JCI Insight       Date:  2018-02-22

5.  Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids.

Authors:  Cosima Arnold; Marija Markovic; Katrin Blossey; Gerd Wallukat; Robert Fischer; Ralf Dechend; Anne Konkel; Clemens von Schacky; Friedrich C Luft; Dominik N Muller; Michael Rothe; Wolf-Hagen Schunck
Journal:  J Biol Chem       Date:  2010-08-23       Impact factor: 5.157

6.  Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study.

Authors:  Satoru Kuriyama; Keitaro Yokoyama; Yoichiro Hara; Naoki Sugano; Takashi Yokoo; Tatsuo Hosoya
Journal:  Clin Exp Nephrol       Date:  2013-11-20       Impact factor: 2.801

Review 7.  Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

Review 8.  Aliskiren--mode of action and preclinical data.

Authors:  Dominik N Müller; Wolfgang Derer; Ralf Dechend
Journal:  J Mol Med (Berl)       Date:  2008-04-29       Impact factor: 4.599

9.  Aliskiren protecting atrial structural remodeling from rapid atrial pacing in a canine model.

Authors:  Zhiqiang Zhao; Yan Chen; Weimin Li; Xinghua Wang; Jian Li; Wansong Yang; Lijun Cheng; Tong Liu; Enzhao Liu; Guangping Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-27       Impact factor: 3.000

Review 10.  The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.

Authors:  Fabrizio Montecucco; Aldo Pende; François Mach
Journal:  Mediators Inflamm       Date:  2009-04-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.